Paclitaxel and docetaxel are excellent agents with a high antitumor effect for the treatment of previously anthracycline-exposed metastatic breast cancer. There has been no standard treatment for patients who undergo therapy of a taxan-resistant metastatic breast cancer. Paclitaxel has partial non-cross-resistance in vitro with docetaxel in inhibiting microtubule disaggregation. We present the case of a patient with docetaxel-refractory anthracycline-pretreated metastatic breast cancer who achieved remission with paclitaxel.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00001813-200008000-00008 | DOI Listing |
Publication Analysis
Top Keywords
metastatic breast
16
breast cancer
16
docetaxel-refractory anthracycline-pretreated
8
anthracycline-pretreated metastatic
8
cancer paclitaxel
8
paclitaxel-induced remission
4
remission docetaxel-refractory
4
metastatic
4
breast
4
cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!